Pravastatin Sodium has 23 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Gemfibrozil, Azithromycin, Clarithromycin. Patients taking Pravastatin Sodium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Contraindicated
- 1
- Major
- 7
- Moderate
- 10
- Minor
- 4
Contraindicated (1)
- Pravastatin Sodium + Gemfibrozil— Concomitant administration should be avoided due to significantly increased risk of myopathy/rhabdomyolysis.
Major (7)
- Pravastatin Sodium + Azithromycin— Potential to increase pravastatin sodium exposures and increase the risk of myopathy and rhabdomyolysis.
- Pravastatin Sodium + Clarithromycin— Increased risk of myopathy and rhabdomyolysis. Pravastatin sodium dose should not exceed 40 mg once daily.
- Pravastatin Sodium + Colchicine— Increases risk of myopathy/rhabdomyolysis with concomitant administration.
- Pravastatin Sodium + Cyclosporine— Increased risk of myopathy and rhabdomyolysis. Pravastatin sodium dose should not exceed 20 mg once daily.
- Pravastatin Sodium + Erythromycin— Increased risk of myopathy and rhabdomyolysis. Pravastatin sodium dose should not exceed 40 mg once daily.
- Pravastatin Sodium + Fibrates— Risk of myopathy and rhabdomyolysis is increased with concomitant use. Monitor for signs and symptoms of myopathy during…
- Pravastatin Sodium + Niacin— Cases of myopathy and rhabdomyolysis observed with concomitant use. Monitor for signs and symptoms of myopathy.
Moderate (10)
- Pravastatin Sodium + Bile Acid Binding Resins— Administer pravastatin sodium at least 1 hour before or at least 4 hours after bile acid sequestrant to avoid reduced ab…
- Pravastatin Sodium + Boceprevir— Increases pravastatin exposure (↑63% AUC). Coadministration increases risk of myopathy.
- Pravastatin Sodium + Cholestyramine Light— Concomitant administration decreases pravastatin AUC by 40-50%; clinically significant timing separation required.
- Pravastatin Sodium + Colestipol— Concomitant administration may decrease pravastatin bioavailability; timing separation recommended.
- Pravastatin Sodium + Darunavir— Combination with ritonavir increases pravastatin exposure (↑81% AUC). Increased risk of myopathy.
- Pravastatin Sodium + Itraconazole— Potent P450 3A4 inhibitor and p-glycoprotein inhibitor increased pravastatin AUC by 1.7-fold and Cmax by 2.5-fold.
- Pravastatin Sodium + Ketoconazole— Cytochrome P450 3A4 inhibitor that may increase pravastatin bioavailability.
- Pravastatin Sodium + Mibefradil— Cytochrome P450 3A4 inhibitor that may increase pravastatin bioavailability.
- Pravastatin Sodium + Pravastatin— Caution should be used when prescribing with pravastatin sodium. Limit pravastatin to 20 mg once daily. Limit pravastati…
- Pravastatin Sodium + Ritonavir— Combined with darunavir, increases pravastatin exposure (↑81% AUC). Increased risk of myopathy.
Minor (4)
- Pravastatin Sodium + Cimetidine— No significant effect on pravastatin AUC when given with cimetidine.
- Pravastatin Sodium + Digoxin— Concurrent administration did not affect digoxin bioavailability parameters.
- Pravastatin Sodium + Diltiazem— Weak cytochrome P450 3A4 inhibitor with no clinically significant effect on pravastatin pharmacokinetics.
- Pravastatin Sodium + Warfarin— Pravastatin 40 mg had no clinically significant effect on warfarin prothrombin time.